Table 1.
Patient and treatment characteristics by allogeneic hematopoietic cell transplant (allo-HCT) vs non-HCT treatment
| Non-HCT | Allo-HCT | P | |
|---|---|---|---|
| n | 132 | 98 | |
| Age, y, median (range) | 56 (19-84) | 47 (19-71) | <.001 |
| Male sex, n (%) | 66 (50) | 58 (59) | >.05 |
| Year diagnosed, n (%) | >.05 | ||
| 2001-2009 | 39 (30) | 24 (24) | |
| 2010-2018 | 93 (70) | 74 (76) | |
| ECOG performance status, n (%) | <.001 | ||
| 0 | 23 (17) | 52 (53) | |
| 1 | 88 (67) | 45 (46) | |
| ≥2 | 21 (16) | 1 (1) | |
| KPS < 90%, n (%) | 48 (36) | 15 (15) | <.001 |
| WBC at diagnosis, n (%) | >.05 | ||
| <30 000 | 72 (55) | 47 (48) | |
| 30 000-100 000 | 33 (25) | 30 (31) | |
| >100 000 | 27 (20) | 21 (21) | |
| BM blasts, median (range) | 85 (4-98) | 81 (10-90) | >.05 |
| CNS involvement, n (%) | 9 (7) | 7 (7) | >.05 |
| BCR-ABL p190 transcript, n (%) | 110 (83) | 71 (82) | >.05 |
| Other cytogenetic changes, n (%) | 87 (67) | 36 (37) | |
| Induction regimen, n (%) | >.05 | ||
| Nonintensive induction | 11 (8) | 8 (8) | |
| Steroid + TKI only | 9 (7) | 8 (8) | |
| Intensive induction | 121 (92) | 90 (92) | |
| Hyper-CVAD-based | 113 (86) | 72 (73) | |
| AYA-inspired | 4 (3) | 12 (12) | |
| Other | 4 (3) | 6 (6) | |
| First-line TKI, n (%) | <.001 | ||
| Imatinib | 32 (24) | 39 (40) | |
| Dasatinib | 62 (47) | 53 (54) | |
| Ponatinib | 38 (29) | 6 (6) | |
| Maintenance TKI, n (%) | <.001 | ||
| Imatinib | 31 (23) | 15 (15) | |
| Dasatinib | 58 (44) | 25 (26) | |
| Ponatinib | 34 (26) | 2 (2) |
AYA, adolescent and young adult. BM, bone marrow; CNS, central nervous system; CVAD, Cyclophosphomide, Vincristine, Doxorubicine, and Dexamethasone; ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell count.